The Headache Inducing Effects of Cilostazol on Migraine Patients

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01841827

Enrollment

Registered

2013-04-29

Start date

2013-04-30

Completion date

2013-06-30

Last updated

2014-06-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Migraine

Brief summary

We will use Cilostazol as a tool to investigate its headache inducing effects in migraine patients.

Interventions

DRUGCilostazol

DRUGPlacebo

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

HEALTH_SERVICES_RESEARCH

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to 60 Years

Healthy volunteers

Inclusion criteria

* Diagnosed with migraine without aura according to the IHS criteria from 2004. * Healthy besides migraine

Exclusion criteria

* Tension-type headache more than 3 days per month * Other types of primary headaches * Pregnancy * History of vascular diseases or psychiatric diseases.

Design outcomes

Primary

Measure	Time frame	Description
The incidens of headache or migraine after adminstration of Cilostazol in migraine patients compared to placebo.	Outcome measure will be done within 3 month. Final data will be presented within 6 months	Rectruitment of 14 patients will be done during April and May. Experiments will be carried out in May and June. Each experiment day takes 1½ hour. Data analysis will be done in June and July. Final data will be presented within 6 months.

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026